Martin A. Graham, PhD
Dr. Martin A Graham is a graduate of Leeds University, England where he earned his BSc in Pharmacology and Microbiology with Joint Honors in 1984. He went on to earn his PhD from the University of London at The Institute of Cancer Research, Royal Marsden Hospital, London UK in 1990. Dr. Graham conducted his post-doctoral research in anti-cancer drug development at the Beatson Institute at University of Glasgow before joining Sterling-Winthrop Pharmaceuticals, which later became Sanofi-Synthelabo, in both the UK and the US. Dr. Graham later served as Director of Pharmacokinetics at Centocor Corporation, a Johnson and Johnson Company; VP of Research and Development at Gemin X biotechnologies; and VP of Development and Regulatory Affairs at TetraLogic Pharmaceuticals.
Dr. Graham founded PKPD Bioscience in 2004 where he currently serves is President and CEO. A decade later he founded KinderPharm in 2014, a pediatric drug development company where Dr. Graham also serves as President and CEO. With his extensive R&D experience with both small molecules and protein therapeutics from IND to NDA/BLA, Dr. Graham has been involved in numerous regulatory filings in the U.S., Japan and Europe for a wide variety of products including Oxaliplatin, Rasburicase, Mitoguazone, Tirapazamine, Alfuzosin, Birinapant, Stelara and Remicade.
Dr. Graham is an Honorary Professor of Pharmacokinetics and Pharmacodynamics at the University of Bradford, Yorkshire, UK and is a specialist in PK/PD modeling clinical trial simulation. He is the author of a text book on the Pharmacokinetics of Cancer Chemotherapy and has substantial publication record in the area of pharmacokinetics, drug metabolism and clinical pharmacology.